Replies to post #104879 on Biotech Values

[DewDiligence]

Inasmuch as BNVI’s PR is a lie, if I were you I would I would take advantage of the opportunity to sell. From the PR you posted:

Bionovo, Inc. (Nasdaq: BNVI, BNVID) announced today that the U.S. Food and Drug Administration (FDA) accepted the Company's Chemistry, Manufacturing and Controls (CMC) plan for its lead drug candidate, Menerba®, in a Type "B" or "End of Phase 2" meeting. With this designation, the decisions and agreements are now considered binding on the Company and the FDA.

As experienced biotech investors know, nothing of this sort is ever binding on the FDA.